4:02 AM
 | 
Sep 20, 2017
 |  BC Extra  |  Company News

Cancer Research, Parker Institutes to test I-O combos for pancreatic cancer

Cancer Research Institute (CRI) and the Parker Institute for Cancer Immunotherapy partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Apexigen Inc. (San Carlos, Calif.) to evaluate combinations of immunotherapies with chemotherapy to treat pancreatic cancer. The partners started a Phase I/II trial to test combinations of BMS's Opdivo nivolumab and Apexigen's APX005M in patients with previously untreated metastatic pancreatic...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >